Definitive Healthcare (NASDAQ:DH) Receives "Underweight" Rating from Barclays

Barclays restated their underweight rating on shares of Definitive Healthcare (NASDAQ:DH - Free Report) in a report released on Monday, Marketbeat reports. Barclays currently has a $4.00 price target on the stock.

DH has been the topic of several other reports. BTIG Research assumed coverage on Definitive Healthcare in a report on Tuesday, September 17th. They issued a "buy" rating and a $7.00 target price on the stock. Stephens started coverage on shares of Definitive Healthcare in a research report on Friday, December 20th. They set an "equal weight" rating and a $5.00 price objective on the stock. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Definitive Healthcare in a research note on Friday, November 8th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Definitive Healthcare presently has an average rating of "Hold" and an average price target of $5.72.

Definitive Healthcare Price Performance

NASDAQ DH traded down $0.29 during trading on Monday, reaching $3.93. The company's stock had a trading volume of 307,922 shares, compared to its average volume of 268,246. Definitive Healthcare has a one year low of $3.19 and a one year high of $10.62. The stock has a market capitalization of $453.99 million, a PE ratio of -1.27, a P/E/G ratio of 3.14 and a beta of 1.40. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49. The firm has a fifty day moving average of $4.37 and a 200 day moving average of $4.52.

Insider Transactions at Definitive Healthcare

In related news, insider William Moschella sold 45,000 shares of the company's stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $4.70, for a total value of $211,500.00. Following the completion of the transaction, the insider now owns 433,830 shares of the company's stock, valued at approximately $2,039,001. This represents a 9.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 14.84% of the company's stock.

Institutional Investors Weigh In On Definitive Healthcare

A number of large investors have recently modified their holdings of the business. Principal Financial Group Inc. grew its holdings in shares of Definitive Healthcare by 10.8% during the 2nd quarter. Principal Financial Group Inc. now owns 39,856 shares of the company's stock worth $218,000 after purchasing an additional 3,874 shares during the period. Rhumbline Advisers lifted its holdings in shares of Definitive Healthcare by 19.7% in the 2nd quarter. Rhumbline Advisers now owns 83,751 shares of the company's stock worth $457,000 after acquiring an additional 13,764 shares during the last quarter. Victory Capital Management Inc. boosted its position in shares of Definitive Healthcare by 1.9% during the 2nd quarter. Victory Capital Management Inc. now owns 509,009 shares of the company's stock worth $2,779,000 after purchasing an additional 9,316 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in Definitive Healthcare by 28.3% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 4,426,420 shares of the company's stock valued at $24,168,000 after purchasing an additional 976,279 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Definitive Healthcare by 50.5% during the second quarter. Renaissance Technologies LLC now owns 28,900 shares of the company's stock worth $158,000 after purchasing an additional 9,700 shares in the last quarter. Hedge funds and other institutional investors own 98.67% of the company's stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.